Table 1 Baseline characteristics of SARS-CoV-2 infected patients included in the study at ICU admission
Variable | n | Overall | No CAPA (n = 130) | CAPA | P-value |
|---|---|---|---|---|---|
(n = 160) | (n = 30) | ||||
Demographic variables | |||||
Age (years) | 160 | 65 [57–71] | 65 [57–71] | 65 [58–70] | 0.92 |
Male gender | 160 | 115 (72%) | 93 (71%) | 22 (73%) | 0.844 |
Coexisting conditions | |||||
Hypertension | 160 | 99 (62%) | 79 (61%) | 20 (67%) | 0.549 |
Diabetes | |||||
Obesity (BMI > 30) | 160 | 51 (32%) | 40 (31%) | 11 (37%) | 0.55 |
Heart disease | 160 | 26 (16%) | 17 (13%) | 9 (30%) | 0.05 |
Chronic kidney disease | 160 | 13 (8%) | 10 (8%) | 3 (10%) | 0.707 |
Liver disease | 160 | 9 (6%) | 6 (5%) | 3 (10%) | 0.371 |
COPD | 160 | 6 (4%) | 4 (3%) | 2 (7%) | 0.313 |
Asthma | 160 | 7 (4%) | 5 (4%) | 2 (7%) | 0.616 |
Chronic neurological disease | 160 | 11 (7%) | 11 (8%) | 0 (0%) | 0.221 |
Active malignancy | 160 | 10 (6%) | 8 (6%) | 2 (6%) | 1 |
Prior transplantation | 160 | 7 (4%) | 5 (4%) | 2 (7%) | 0.616 |
Immunosuppression | 160 | 2 (1%) | 1 (1%) | 1 (3%) | 0.341 |
Laboratory analysis | |||||
Blood counts | |||||
-Leukocytes [G/I] | 157 | 11.2 [7.6–15] | 11.2 [7.4–15.2] | 11.8 [8.9–13.9] | 0.585 |
-Neutrophils [G/I] | 157 | 10.2 [6.9–14] | 10.1 [6.5–12.9] | 11.2 [8.0-14.1] | 0.292 |
-Lymphocytes [G/I] | 157 | 0.6 [0.5–0.9] | 0.7 [0.5–0.9] | 0.6 [0.4–1.1] | 0.927 |
-Thrombocytes [G/I] | 157 | 241 [180–313] | 243 [181–319] | 237 [172–310] | 0.698 |
Specific Medication | |||||
Glucocorticoids | 139 | 121 (87%) | 97 (86%) | 24 (92%) | 0.525 |
Remdesivir | 139 | 11 (8%) | 7 (6%) | 4 (15%) | 0.125 |
Lopinavir/ritonavir | 139 | 27 (19%) | 21 (19%) | 6 (23%) | 0.602 |
Tocilizumab | 139 | 24 (17%) | 22 (19%) | 2 (8%) | 0.248 |